Added to YB: 2024-12-13
Pitch date: 2024-12-12
SRPT [neutral]
Sarepta Therapeutics, Inc.
-82.52%
current return
Author Info
Two Natural Capital writes about markets, particularly focused on life sciences/biotech. Sign up for the newsletter.
Company Info
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
Market Cap
$2.0B
Pitch Price
$123.19
Price Target
N/A
Dividend
N/A
EV/EBITDA
25.37
P/E
-6.79
EV/Sales
0.99
Sector
Biotechnology
Category
growth
Sarepta Therapeutics: From Exon-Skipping to Gene Therapy $srpt
SRPT (overview): DMD gene therapy ELEVIDYS approved for 80% of US patients. $3.2M/patient vs $750K-1.5M/yr for exon skipping. 2025 rev $2.9-3.1B (2/3 ELEVIDYS). 10.7x 2025 P/E. Risks: limited efficacy, potential competition, high mgmt confidence in guidance. Pipeline includes LGMD therapy.
Read full article (6 min)